In the treatment of RA, emodin acts on synovial cells to inhibit inflammation by activating or inhibiting various signaling pathways, such as the JAK/STAT, NF-κB, and OPG/RANK-RANKL pathways (Table 1). Here, NFKB1 is linked to rheumatoid arthritis.